BCL2L1 and prostate carcinoma: In addition, ABT-263 improved cancer cell cytotoxicity in androgen-dependent prostate cancer cells undergoing androgen-deprivation therapy and interfered with progression to androgen-independent prostate cancer, demonstrating a potent effect of Bcl-2/Bcl-xL inhibition at early stages of prostate cancer [68,69].